Dhruv Sareen

US Patent:

20210269776, Sep 2, 2021

Filed:

Jun 26, 2019

Appl. No.:

17/254783

Inventors:

- Los Angeles CA, US
Dhruv Sareen - Porter Ranch CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12N 5/071
C12N 5/074
B33Y 30/00
B33Y 70/00

Abstract:

Bioprinting is the layer-by-layer construction of synthetic tissues or scaffolds. Described herein is a motorized extruder which can precisely extrude and retract extrudate such as bioinks in a compact and rapidly-loadable form-factor. This includes a compact bioprinter using a stepper motor coupled with a threaded shaft to directly move the plunger of an extruder. This pneumatic-mechanical system obviates the needs for pneumatic tubing, rods, or other complex elements of existing designs. The direct drive design further allows for a lighter, smaller gantry that is capable of more precise fabrication of bioprinted constructions. This includes delicate vasculature systems that are beyond limits of existing bioprinting technologies.

US Patent:

20210000880, Jan 7, 2021

Filed:

Mar 22, 2019

Appl. No.:

16/982691

Inventors:

- Los Angeles CA, US
Dhruv Sareen - Porter Ranch CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

A61K 35/39
C12N 5/071

Abstract:

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.

US Patent:

20200332316, Oct 22, 2020

Filed:

Jun 30, 2020

Appl. No.:

16/917008

Inventors:

- Los Angeles CA, US
Dhruv Sareen - Porter Ranch CA, US
Loren A. Ornelas - Los Angeles CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12N 15/85
C12N 5/074

Abstract:

Described herein are reprogramming techniques allowing for production of mammary-derived iPSCs (“m-iPSCs”). The m-iPSCs described herein exhibit all the hallmarks of stem cell identity including round cluster, bright colony morphology, clonal expansion, and pluripotent marker expression (alkaline phosphatase expression, Oct-4, nanog, etc.) Further refined techniques allow for generation of m-iPSCs under essentially defined conditions.

US Patent:

20200224159, Jul 16, 2020

Filed:

Oct 5, 2018

Appl. No.:

16/340185

Inventors:

- Ahmenabad, Gujarat, IN
Rajani BATTU - Anandnagar, Bangalore, IN
Reena RATHOD - Nagar, Bangalore, IN
Harshini SURENDRAN - Tamil Nadu, IN
Kapil BHARTI - Potomac MD, US
Deepak LAMBA - San Anselmo CA, US
Dhruv SAREEN - Northridge CA, US
Mahendra RAO - Timonium MD, US
Sushma NANJUNDA SWAMY - Bangalore-Karnataka, IN
Vijay Bhaskar KONALA REDDY - Vishakapatnam-Andhra Pradesh, IN
Mohanapriya RAJAMOORTHY - Dharmapuri - Tamil Nadu, IN

International Classification:

C12N 5/079
A61K 35/30
A61K 35/545

Abstract:

A unified cell differentiation protocol for obtaining photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid from pluripotent stem cells is described. Also described are photoreceptor cells, retinal pigmented epithelium, and 3D retinal organoid obtained from pluripotent stem cells. Also described are a pharmaceutical composition and a medicament containing the photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid as described.

US Patent:

20200157508, May 21, 2020

Filed:

May 18, 2018

Appl. No.:

16/614924

Inventors:

- Los Angeles CA, US
Clive Svendsen - Pacific Palisades CA, US
Stephan R. Targan - Santa Monica CA, US
Michael Workman - Santa Monica CA, US
Dhruv Sareen - Porter Ranch CA, US

Assignee:

Cedares-Sinai Medical Center - Los Angeles CA

International Classification:

C12N 5/071
A01N 1/02

Abstract:

Induced pluripotent stem cell (iPSC)-based organoid technology has tremendous potential to elucidate the intestinal and colonic epithelium's role in health and disease. Described herein are methods and compositions for generation of intestinal and colonic cells from iPSCs. Derivation of iPSCs from subjected afflicted with early onset and very early onset Inflammatory Bowel Disease (IBD), serves as an excellent model for understanding disease pathogenesis.

US Patent:

20200002671, Jan 2, 2020

Filed:

Jan 25, 2018

Appl. No.:

16/480778

Inventors:

- Los Angeles CA, US
Xiaojiang CUI - Arcadia CA, US
Dhruv SAREEN - Porter Ranch CA, US
Armando E. GIULIANO - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

C12N 5/071
A61K 35/55
C12N 5/074

Abstract:

Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.

US Patent:

20190359924, Nov 28, 2019

Filed:

Feb 26, 2019

Appl. No.:

16/286185

Inventors:

- Boston MA, US
- Los Angeles CA, US
Carolina Lucchesi - Westwood MA, US
Christopher David Hinojosa - Malden MA, US
Jacob Fraser - Somerville MA, US
Geraldine Hamilton - Boston MA, US
Gad Vatine - Los Angeles CA, US
Samuel Sances - Santa Monica CA, US
Clive Svendsen - Pacific Palisades CA, US
Daniel Levner - Brookline MA, US
Dhruv Sareen - Porter Ranch CA, US

International Classification:

C12M 3/06
C12N 5/0793
C12N 5/071
C12N 5/079
B01L 3/00
C12M 1/12
C12N 5/00

Abstract:

The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.

US Patent:

20190194606, Jun 27, 2019

Filed:

Aug 29, 2017

Appl. No.:

16/329659

Inventors:

- Los Angeles CA, US
Sam SANCES - Santa Monica CA, US
Clive SVENDSEN - Pacific Palisades CA, US
Dhruv SAREEN - Porter Ranch CA, US
Alexis J. KERL - Los Angeles CA, US

Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA

International Classification:

C12N 5/00
C12N 5/0797
C12M 3/06
B01L 3/00
C12M 1/12
C12N 5/071

Abstract:

Described here are systems and methods for deriving both spinal motor neurons and brain microvascular endothelial cells from induced pluripotent stem cells using distinct methods and combining them in a chip format. Neurons cultured alone in chip microvolume displayed increased calcium transient function and chip-specific gene expression. When seeded with endothelial cells, interaction further enhanced neural function, elicited vascular-neural interaction, niche gene expression with enhanced in vivo-like signatures arising from the chip co-cultures. Development of novel media formulations further allow for improved readout of differentiation process, by eliminating additives that otherwise confound differentiation processes and resulting phenotypes.